跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

555552

Sigma-Aldrich

Rho Kinase Inhibitor

InSolution, ≥95%

别名:

InSolution Rho Kinase Inhibitor

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥95% (HPLC)

表单

liquid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

储存温度

−20°C

一般描述

A cell-permeable isoquinolinesulfonamide compound that acts as a highly specific, potent, and ATP-competitive inhibitor of G-protein Rho-associated kinase (ROCK; Ki = 1.6 nM). Inhibits other serine/threonine kinases only at higher concentrations (Ki = 630 nM for PKA, 9.27 µM for PKC, and 10.1 µM for MLCK). Shown to selectively block lysophosphatidic acid-induced, but not PDBu-induced, phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in NT-2 cells (IC50 = 2.5 µM). Reported to be a more potent and selective inhibitor than Y-27632 (Cat. No. 688000 & 688001).
The InSolution Rho Kinase Inhibitor controls the biological activity of Rho Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

生化/生理作用

Cell permeable: no
Primary Target
ROCK
Product competes with ATP.
Target Ki: 1.6 nM against Rho-associated kinase (ROCK)

警告

Toxicity: Harmful (C)

外形

A 10 mM (500 µg/128 µl) solution of Rho Kinase Inhibitor (Cat. No. 555550) in H₂O.

重悬

Following initial thaw, aliquot and freeze (-20°C).

其他说明

Ikenoya, M., et al. 2002. J. Neurochem.81, 9.
Sasaki, Y., et al. 2002. Pharmacol. Ther.93, 225.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

储存分类代码

12 - Non Combustible Liquids

WGK

nwg

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Harini Narasimhan et al.
Biology, 11(10) (2022-10-28)
TNBC represents the most aggressive breast cancer subtype. Although cancer stem cells (CSCs) are a minor fraction of all cancer cells, they are highly cancerous when compared to their non-stem counterparts, playing a major role in tumor recurrence and metastasis.
Katrin Raute et al.
Cancer immunology research, 11(6), 810-829 (2023-05-04)
There are no targeted therapies for patients with triple-negative breast cancer (TNBC). TNBC is enriched in breast cancer stem cells (BCSC), which play a key role in metastasis, chemoresistance, relapse, and mortality. γδ T cells hold great potential in immunotherapy
Jessalyn M Ubellacker et al.
Nature, 585(7823), 113-118 (2020-08-21)
Cancer cells, including melanoma cells, often metastasize regionally through the lymphatic system before metastasizing systemically through the blood1-4; however, the reason for this is unclear. Here we show that melanoma cells in lymph experience less oxidative stress and form more
Xiao Li et al.
International journal of molecular sciences, 21(2) (2020-01-16)
Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen and progesterone receptors (ER, PR) and lacking an overexpression of human epidermal growth factor receptor 2 (HER2). Apart from this lack of therapeutic targets

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门